Building a longevity intelligence
platform for India.

Market reality & opportunity

The global longevity market is no longer a niche. It is a $29B convergence of diagnostic technology, consumer health awareness, and data-driven medicine. India is one of the fastest-growing regions in this category — and Hyderabad has zero serious players. The window is open right now.

The macro landscape

The longevity market reached approximately $29 billion in 2026 and is projected to grow to $67 billion by 2035 at a 9.4% compound annual growth rate. What used to be a fringe category is now a serious, data-driven sector spanning diagnostics, supplements, wearables, clinics, and emerging therapeutics. Consumer-facing longevity platforms — Function Health, Neko Health, Viome, Tally Health, Acorn Biolabs — collectively raised over $700M in 2024-2025, demonstrating that capital is flowing to consumer intervention models, not just drug pipelines.

Why now: three converging tailwinds

Competitive landscape — global benchmarks

Five companies define what a credible consumer longevity platform looks like today. Each one validates the category's commercial viability — and each one leaves a distinct gap that is relevant to our positioning.

The Indian opportunity in detail

Biopeak's positioning reveals exactly what they cannot serve: the urban professional aged 28-45 earning ₹25-75 lakh annually who wants serious, biomarker-driven health optimization but cannot justify ₹1.1 lakh on a single assessment, doesn't want a 6-hour clinic visit, and lives outside Bangalore. That is a market measured in hundreds of thousands of customers — not the few thousand who can afford Biopeak.

The gap nobody is filling

Positioning & competitive edge

What we are, what we are not, and why people pay us. Positioning is not what we say — it is the position we occupy in the customer's mind relative to every alternative they could choose. Get this right and everything else gets easier.

The core positioning statement

Notice what this is not: it is not a wellness app, not a gym, not a generic health coaching service, not anti-aging supplements, not a clinic. It is a structured, clinically-grounded intervention with before/after proof. The biological age score is not a feature of the product — it is the entire product. Every other component (the bloodwork, the protocol, the coaching, the doctor) exists to make that score move.

Language that builds trust vs. language that kills it

Your customer has been marketed to by every wellness brand on the internet. They are pattern-matching for credibility signals. The wrong language triggers immediate skepticism — even if the product behind it is excellent. The right language earns the benefit of the doubt long enough for them to read the next sentence.

Your target customer — be precise

The clearer your customer definition, the cheaper your acquisition cost and the higher your conversion rate. Your customer is not "health-conscious adults." That description includes everyone from a 22-year-old gym bro to a 65-year-old grandmother. Both should be filtered out. This is who you're actually serving:

Your four defensible moats

Most early-stage health startups have no real moat. They are a service business with marketing. Your moat is built deliberately, in stages, and compounds over time. Here are the four to focus on, in order of when each becomes defensible:

How to differentiate from Biopeak specifically

Biopeak is the closest comparable — same country, same broad category, well-funded, scientifically credible. The instinct is to ask: how are we different? But the better question is: who are we serving that they aren't? Differentiation by customer is far stronger than differentiation by feature.

MVP & product definition

The minimum product that can earn real money and real trust. Not an app. Not a platform. Not a clinic. A human-delivered, data-backed 90-day program that we sell first and build the technology around afterwards. This is exactly how Biopeak, Function Health, and every credible health startup began.

The 90-day metabolic performance program

Phase 1 — Deep assessment (Week 1)

Within seven days of the client's signup, we complete a comprehensive baseline. The bloodwork is the foundation — but the lifestyle intake and wearable data baseline are equally important, because they tell us where the protocol's leverage points are likely to be.

• Comprehensive bloodwork (40-60 markers). Full lipid panel including ApoB and Lp(a) — not just basic LDL/HDL/TG. Fasting glucose, insulin, HbA1c. Inflammation: hsCRP, IL-6, homocysteine. Complete hormonal panel: testosterone (men), estradiol (women), full cycle profile, cortisol curve. Thyroid: TSH, T3, T4, antibodies. Vitamin D, B12, ferritin, magnesium. Kidney and liver function.
• Biological age calculation. Composite biological age using PhenoAge (Levine 2018, peer-reviewed and validated). Requires nine standard bloodwork markers we already have. This becomes the headline number — the "before" score the client photographs and shares.
• Wearable data baseline. Two weeks of existing data: HRV trends, sleep stage distribution, resting heart rate, respiratory rate. Pulled from their Oura, Whoop, Apple Watch, or Fitbit. Surfaces patterns they don't see themselves.
• Lifestyle intake (45-minute video). Detailed questionnaire on eating patterns, meal timing, training history, sleep hygiene, stress triggers, supplement history, family medical history, alcohol, tobacco. Conducted as a structured conversation, not a form fill.

Phase 2 — Personalized intervention (Weeks 2-10)

The protocol covers four levers — nutrition, training, recovery, supplementation — each calibrated to the client's specific data, not generic guidelines. The protocol is reviewed by our medical advisor before delivery. The client gets a written protocol document, bi-weekly video check-ins, and daily WhatsApp accountability.

Phase 3 — Re-measurement (Day 90)

The same 40-60 biomarker panel, the same lab, the same fasted protocol, the same time of day. We recalculate biological age. We compare every marker individually. Then we deliver a 20-30 page outcome report that shows what moved, by how much, and which protocol elements likely drove the change. This is the moment most people have never had — proof that what they did actually worked.

Phase 4 — Adapt (Day 91 onwards)

Three paths: continuation with refinements (most common — clients renew into the next 90 days), escalation to a deeper Pro or Continuum program if some markers need more aggressive intervention, or graduation to quarterly maintenance — light-touch monitoring with one bloodwork panel every 90 days and protocol updates.

The technology stack — keep it boring in Year 1

Delivery model — remote-first, not clinic-dependent

The remote-first model is operationally simpler, geographically scalable, and produces a better customer experience. The one physical touchpoint worth adding — and this is optional — is an in-person kickoff session in Hyderabad: 90 minutes at a coworking space or quiet café, sitting with the client to walk through their bloodwork in person. That moment of human contact drives retention and referrals more than a clinic visit would.

Revenue model & unit economics

Pricing, margins, customer lifetime value, and the operational path to ₹1 crore ARR within 18 months. Most early-stage health businesses underprice their offering because they're afraid of customer objections — but underpricing kills credibility faster than high pricing does in this category.

Pricing tiers — research-validated

Unit economics

Path to ₹1 crore ARR — 18 month plan

B2B corporate — your fastest revenue lever

Corporate B2B should not be your first revenue source. You need real case studies before any CHRO will take a meeting seriously. But once you have them, B2B is the fastest path from ₹50L ARR to ₹2Cr+ ARR — far faster than scaling individual B2C client acquisition. Three corporate deals equals 200+ B2C clients in revenue terms, with significantly less operational complexity per rupee earned.

Revenue mix evolution

Go-to-market strategy

Concrete channels and actions for your first 100 clients. Not generic marketing advice — specific plays for the Hyderabad market, sequenced by phase, with realistic conversion expectations.

Phase 1 — Manual acquisition (Month 1-3, target: 10-20 clients)

Phase 2 — Proof-driven growth (Month 4-9, target: 20-50 clients)

By month four you have real case studies. Now you have proof. Everything becomes easier — outreach, conversion, doctor partnerships, corporate sales. This is the phase where the business starts looking like a real business.

Phase 3 — Scalable channels (Month 10-18)

• Paid LinkedIn ads targeting Hyderabad tech founders, VPs, CHROs aged 30-50. Retarget LinkedIn content viewers first — this is the lowest CAC channel.
• YouTube series: "Longevity Lab" — translating bloodwork into plain-English insight. 5-10 minute episodes. Builds organic authority and search traffic.
• Instagram educational content: biological age explainers, biomarker breakdowns, client transformation stories. Repurposes LinkedIn content for a different audience surface.
• Private community (WhatsApp or Circle): existing clients + interested waitlist. Becomes your strongest referral and retention engine.
• Strategic PR: pitch Hyderabad-based tech and health journalists on the "India's first biological age tracking program" angle. One good feature in YourStory or Inc42 = 20-30 warm inbound leads.

Referral economics — your most powerful growth engine

7-year roadmap

Honest phases with revenue targets, hiring plans, and product milestones. The headline: prove the model in year one, build the platform in year two, scale across India in years three to four, and transition into a deep-tech research company in years four to seven.

Hiring plan — the right people, in the right order

Risks, funding & execution principles

What will kill this business if we let it. How to prevent each one. Where the capital comes from at each stage. And the six non-negotiable principles that should guide every operational decision in the first three years.

Risk register — ranked by probability

Funding strategy — when to raise, how much, from whom

The six non-negotiable execution principles

End of strategy document v1.0 · April 2026 · Confidential · Tessera Health